---
title: Cell Therapy/Immuno-Oncology Preclinical Models - TD2 Precision Oncology
description: Preclinical CAR-T experience in both solid and hematologic tumors offers epert study design and fast study initiation for developing cell therapies.
image: https://td2inc.com/hubfs/Assets/Images/cell-therapy-diagram.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
## Preclinical Capabilities
# Cell Therapy/Immuno-Oncology Preclinical Models
### Trusted immune-oncology models for optimal CAR-T study design
TD2 is your trusted, experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy studies. Our extensive knowledge of CAR-T in both solid and hematologic tumors enables optimal study design and rapid study initiation.
Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Having performed hundreds of studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.
TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability.
### **Cell Therapy Capabilities of 400+ Cell line derived xenograft (CDX) models include:**
- Optical imaging (Bioluminescence and Fluorescence)
- Orthotopic and surgical
- IP Dissemination
- IV Dissemination
- Hematological
- Biodistribution
- Non-GLP Toxicity
### Learn more about our CAR-T services.
Contact our experts to help advance your adoptive cell therapy with our trusted preclinical research services.
**Figure A.** CAR-T Cell Treatment on subQ Hs7666T
Pancreatic Cell Line. 5 x 106 CAR-T Cells given on Day 1
**Figure B.** CAR-T Cell Treatment on IV disseminated
Nalm-6-luc ALL Cell Line. 4 x106 CAR-T Cells given on Day 4
### Commonly Utilized Cell Lines (Contact Us for Full Cell Line List)
| [786-0 Human Renal Cell Carcinoma](https://td2inc.com/786-0-cdx-model/?hsLang=en) | [KKU-M213 human intrahepatic cholangiocarcinoma](https://td2inc.com/kku-m213-cdx-model/?hsLang=en) |
| --- | --- |
| [A2780: Human Ovarian](https://td2inc.com/a2780-cdx-model/?hsLang=en) | [MCF-7 Human Breast](https://td2inc.com/mcf-7-cdx-model/?hsLang=en) |
| [A498: Human Renal Cell Carcinoma](https://td2inc.com/a498-cdx-model/?hsLang=en) | [MM1.s Human Multiple Myeloma](https://td2inc.com/mm1-s-cdx-model/?hsLang=en) |
| [ACHN Renal Cell Adenocarcinoma](https://td2inc.com/achn-cdx-model/?hsLang=en) | [Nalm6-Fluc-GFP Acute Lymphoblastic Leukemia](https://td2inc.com/nalm6-fluc-gfp-cdx-model/?hsLang=en) |
| [BxPC3 Human Pancreas](https://td2inc.com/bxpc3-cdx-model/?hsLang=en) | [Nalm-6 Human Acute Lymphoblastic Leukemia](https://td2inc.com/nalm-6-cdx-model/?hsLang=en) |
| [Caki-1 Human Renal Cell Carcinoma](https://td2inc.com/caki-1-cdx-model/?hsLang=en) | [NCI-H660 Human Prostate Neuroendocrine](https://td2inc.com/nci-h660-cdx-model/?hsLang=en) |
| [Caki-2 Human Renal Cell Carcinoma](https://td2inc.com/caki-2-cdx-model/?hsLang=en) | [NCI-H1963 Human Lung](https://td2inc.com/nci-h1963-cdx-model/?hsLang=en) |
| [CCRF-CEM Human Acute T Cell Lymphoblastic Leukemia](https://td2inc.com/ccrf-cem-cdx-model/?hsLang=en) | [NCI-H1975 Human Non-Small Cell Lung](https://td2inc.com/nci-h1975-cdx-model/?hsLang=en) |
| [H69 Human Small Cell Lung](https://td2inc.com/h69-cdx-model/?hsLang=en) | [NCI-N87 Human Gastric](https://td2inc.com/nci-n87-cdx-model/?hsLang=en) |
| [H209 Human Lung](https://td2inc.com/h209-cdx-model/?hsLang=en) | [OV90 Human Ovarian](https://td2inc.com/ov90-cdx-model/?hsLang=en) |
| [HCC70 Human Breast](https://td2inc.com/hcc70-cdx-model/?hsLang=en) | [OVCAR-3 Human Ovarian](https://td2inc.com/ovcar-3-cdx-model/?hsLang=en) |
| [HCC1954 Human Breast](https://td2inc.com/hcc1954-cdx-model/?hsLang=en) | [Raji Human Burkett’s Lymphoma](https://td2inc.com/raji-cdx-model/?hsLang=en) |
| [HCT116 Human Colon](https://td2inc.com/hct116-cdx-model/?hsLang=en) | [RPMI-8226 Human Myeloma](https://td2inc.com/rpmi-8226-cdx-model/?hsLang=en) |
| [HH Human Cutaneous T Cell Lymphoma](https://td2inc.com/hh-cdx-model/?hsLang=en) | [SKOV-3 Human Ovarian](https://td2inc.com/skov-3-cdx-model/?hsLang=en) |
| [Hs766T Human Pancreas](https://td2inc.com/hs766t-cdx-model/?hsLang=en) | [SNU-1 Human Gastric Carcinoma](https://td2inc.com/snu-1-cdx-model/?hsLang=en) |
| [HT-55 Human Colorectal](https://td2inc.com/ht-55-cdx-model/?hsLang=en) | [SW-480 Human Colon](https://td2inc.com/sw-480-cdx-model/?hsLang=en) |
| [HuT78 Human Cutaneous T Lymphocyte](https://td2inc.com/hut78-cdx-model/?hsLang=en) | [SW-620 Human Colon](https://td2inc.com/sw-620-cdx-model/?hsLang=en) |
| [Jeko-1 Human Mantle Cell Lymphoma](https://td2inc.com/jeko-1-cdx-model/?hsLang=en) | [THP-1 Human Acute Myeloid Leukemia](https://td2inc.com/thp-1-cdx-model/?hsLang=en) |
| [Jurkat-Luc Human Acute T Cell Leukemia](https://td2inc.com/jurkat-luc-cdx-model/?hsLang=en) | [Toledo Human Diffuse Large B-Cell Lymphoma](https://td2inc.com/toledo-cdx-model/?hsLang=en) |
---
#### TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR-T cell mouse studies across multiple antigen targets in a number of oncology indications.
- **Dr. Jon Terrett** Head of Immuno-Oncology Research and Translation CRISPR Therapeutics
### IMMUNO-ONCOLOGY
## Comprehensive preclinical services for immuno-oncology.
TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.
Large panel of human and murine tumor models
[Syngeneic mouse models](https://td2inc.com/syngeneic-models/?hsLang=en)
---
- Fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors
Humanized mice
---
- Human PBMCs or effector cell engraftment
- Sourced CD34+ humanized mice
- [Humanized immune checkpoint inhibitor mice](https://td2inc.com/humanized-immune-checkpoint-inhibitor-mouse-models/?hsLang=en)
## Additional Resources
[](https://blog.td2inc.com/the-significance-of-preclinical-evaluation-in-car-t-cell-therapy-for-solid-and-hematologic-tumors?hsLang=en)
Blog
## [The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors](https://blog.td2inc.com/the-significance-of-preclinical-evaluation-in-car-t-cell-therapy-for-solid-and-hematologic-tumors?hsLang=en)
[](https://blog.td2inc.com/car-t-cell-program-development-key-considerations?hsLang=en)
Blog
## [CAR T-cell Program Development: Key Considerations](https://blog.td2inc.com/car-t-cell-program-development-key-considerations?hsLang=en)
[](https://td2inc.com/lp-video-td2s-cell-therapy-capabilities/?hsLang=en)
Videos
## [Cell Therapy at TD2](https://td2inc.com/lp-video-td2s-cell-therapy-capabilities/?hsLang=en)
[](https://td2inc.com/lp-video-car-t-summit-tech-slam/?hsLang=en)
Videos
## [CAR-T Summit Tech Slam](https://td2inc.com/lp-video-car-t-summit-tech-slam/?hsLang=en)
Load More
## GET STARTED
## Work with a team who believes in your research as much as you do.
Are you ready to start your preclinical studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)